NCT00455052View on ClinicalTrials.gov

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Small Cell Lung CancerNon-small Cell Lung Cancer
Interventions
DRUG

XMT-1001

XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.

Trial Locations (12)

12208

New York Oncology Hematology, New York

21201

University of Maryland, Greenebaum Cancer Center, Baltimore

23502

Virginia Oncology Associates, Norfolk

29605

Institute of Translational Oncology Research, Greenville

46219

Central Indiana Cancer Centers, Indianapolis

75702

Texas Oncology - Tyler, Tyler

80218

Rocky Mountain Cancer Centers, Denver

85258

TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

97477

Willamette Valley Cancer Institute and Research Center, Springfield

98684

Vancouver Cancer Center, Vancouver

99218

Evergreen Hematology & Oncology, Spokane

Sponsors
All Listed Sponsors
lead

Mersana Therapeutics

INDUSTRY

NCT00455052 - A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter